Allergy Diagnostics Market Report 2026

The allergy diagnostics market size has grown rapidly in recent years. It will grow from $6.99 billion in 2025 to $7.94 billion in 2026 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to increasing prevalence of allergies worldwide, adoption of skin prick and intradermal tests, expansion of hospital-based laboratories, growing awareness about allergy management, limited availability of advanced in-vitro kits.

The allergy diagnostics market size is expected to see rapid growth in the next few years. It will grow to $13.03 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to advancement in component-resolved diagnostics, integration of automation in allergy testing, rising investment in research on novel allergens, growth of academic and diagnostic laboratories, increasing demand for personalized allergy treatment. Major trends in the forecast period include rising demand for accurate allergy diagnostics, growing adoption of in-vitro testing methods, expansion of food and drug allergen testing, increased use of elisa, rast, and crd kits, focus on rapid and point-of-care allergy detection.

The rising prevalence of allergic diseases is expected to drive the growth of the allergy diagnostics market. The increase in allergy cases has been linked to higher environmental pollution from traffic and various industries. An allergic reaction occurs when the immune system responds abnormally to an allergen. Common allergic diseases include anaphylaxis, allergic rhinitis (commonly known as ‘hay fever’), food allergies, skin allergies, and allergic asthma. Avoiding exposure to allergens remains the most important approach to managing allergic conditions. Therefore, accurate allergy diagnosis is critical for effective treatment. For example, in September 2024, Anaphylaxis UK, a UK-based charity, reported that 20% of food allergy reactions take place in schools. One in five children with food allergies face bullying, and one in five parents experience moderate to severe anxiety. Almost all parents of affected children show post-traumatic stress symptoms (PTSS), with rates seven times higher among parents whose children use adrenaline auto-injectors (AAIs). Therefore, the growing incidence of allergic diseases is expected to further support the expansion of the allergy diagnostics market.

Major players in the allergy diagnostics market are developing new technologies, such as AI-powered allergy component testing platforms, to enhance their market profitability. An AI-powered allergy component testing platform is an advanced system that uses artificial intelligence (AI) to analyze and interpret allergy test results. For instance, in May 2023, Metropolis, an India-based pathology lab and diagnostic center, launched an AI-powered platform capable of identifying 127 respiratory allergens, 10 contact allergens, and 158 food allergens. This testing platform provides valuable insights for determining and optimizing treatment plans for individual allergy conditions and assists clinicians in making informed decisions through the use of component-resolved diagnostics (CRD) and AI.

In July 2024, Roche, a Switzerland-based pharmaceutical company, acquired LumiraDx for an undisclosed amount. This acquisition aims to strengthen Roche's diagnostics portfolio by integrating LumiraDx's technologies, which are expected to significantly improve patient access to diagnostic testing, particularly in primary care settings. LumiraDx is a US-based healthcare company specializing in microfluidic immunofluorescence assays.

Major companies operating in the allergy diagnostics market are bioMérieux SA, Danaher Corporation, HOB Biotech Group Corp. Ltd., HYCOR Biomedical, Lincoln Diagnostics Inc., Omega Diagnostics Group PLC, Siemens Healthineers AG, Thermo Fisher Scientific Inc., PerkinElmer Inc., R-Biopharm AG, Abbott Laboratories, HollisterStier Allergy, NEOGEN Corporation, AESKU.GROUP GmbH, ACON Laboratories Inc., Erba Group, Stallergenes Greer, HAL Allergy Group, INDOOR Biotechnologies Inc., MacroArray Technologies LLC, Phadia AB, Quest Diagnostics, Randox Laboratories Ltd., Eurofins Viracor Inc., VRL Laboratories.

North America was the largest region in the allergy diagnostics market in 2025. The regions covered in the allergy diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allergy diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the allergy diagnostics market by increasing the cost of imported instruments, reagents, and consumables used in in-vitro and in-vivo testing. Segments such as ELISA kits, luminometers, and other advanced testing instruments are most impacted, with north america, europe, and asia-pacific regions experiencing higher import costs and supply chain delays. While tariffs increase operational expenses, they also encourage local manufacturing of diagnostic instruments and reagents, fostering regional production capabilities and innovation in rapid allergy testing technologies.

The allergy diagnostics market research report is one of a series of new reports that provides allergy diagnostics market statistics, including allergy diagnostics industry global market size, regional shares, competitors with a allergy diagnostics market share, detailed allergy diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the allergy diagnostics industry. This allergy diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Allergy diagnostics involves a variety of tests and procedures designed to identify specific allergens, such as foods, pollens, or chemicals, that trigger allergic reactions. Its primary purpose is to accurately detect allergens, enabling healthcare providers to recommend appropriate treatments. This helps improve the management of allergic conditions.

The main categories of allergy diagnostic tests are in-vivo allergy tests and in-vitro allergy tests. In-vivo allergy tests are conducted directly on the human body to determine the cause of the allergic reaction. In-vitro allergy tests are carried out in laboratories using test tubes and Petri dishes to identify substances responsible for the allergy. The primary products used in allergy diagnostics include consumables, instruments, and luminometers. Based on allergens, the allergy diagnostics market is divided into inhaled allergens, food allergens, and drug allergens. Key end-users of allergy diagnostics include diagnostic laboratories, hospital-based laboratories, and academic and research institutes.

The allergy diagnostics market includes revenue earned by instruments such as immunoassay analyzers, ELISA analyzers, luminometers, and other instruments that are used to diagnose allergies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.